Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
David Wyles, Heiner Wedemeyer, Ziv Ben‐Ari, Edward J. Gane, Jesper Bach Hansen, Ira M. Jacobson, Alex L. Laursen, Annie Luetkemeyer, Ronald Nahass, Stephen Pianko, Stefan Zeuzem, Patricia Jumes, Hsueh‐Cheng Huang, Joan Butterton, Michael Robertson, Janice Wahl, Eliav Barr, Hee‐Koung Joeng, Elizabeth Martin, Lawrence Serfaty, for the C‐CREST Part C and C‐SURGE Investigators – 7 July 2017 – People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population.